drugset / Trial / NCT05388487
Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors
Phase 1
Unknown
54 enrolled
HighField Biopharmaceuticals Corporation
Tigermed Consulting Co., Ltd · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA) for the induction of remission in patients with acute promyelocytic leukemia (APL) and for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs).
Timeline
- Start
- 2022-02-16
- Primary completion
- 2025-04
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tretinoin | Unknown | 45 mg/m2 | Other |
| Subject | Tretinoin | Unknown | 90 mg/m2 | Other |
| Subject | Tretinoin | Unknown | 120 mg/m2 | Other |
| Subject | Tretinoin | Unknown | 160 mg/m2 | Other |
| Subject | Tretinoin | Unknown | 180 mg/m2 | Other |